Skip to main content
Martha A. Salek, MD, MPH
Marta A. Salek, MD, MPH

Marta A. Salek, MD, MPH

Instructor, St. Jude Faculty

Departments

Education

BS - The University of Western Ontario (UWO), London, Ontario, Canada
MD - Jagiellonian University Medical College (JUMC), Krakow, Poland
Residency (Pediatrics) - University of Massachusetts (UMMS) - Baystate Children’s Hospital, Springfield, MA
Fellowship (Palliative and Hospice Medicine) - University of Washington / Seattle Children’s Hospital, Seattle, WA
Fellowship (Pediatric Hematology/Oncology), St. Jude Children’s Research Hospital, Memphis, TN         
MPH - Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Honors & Awards

  • Global Oncology Young Investigator Award, ASCO, Conquer Cancer Foundation                                   
  • Merit Award, ASCO Quality Care Symposium                                                               

Research Interests

  • Early integration of palliative care in pediatric oncology
  • Decision making for children diagnosed with advanced cancer
  • Optimizing care and quality of life for children diagnosed with cancer on a global scale

Selected Publications

Salek M, Woods C, Gattas M, Gattuso JS, Mandrell B, Baker, JN, Kaye EC. Multidisciplinary Clinician Perspectives on Embedded Palliative Oncology Models in Pediatric Cancer. J Pain Symptom Mange 2022. Online ahead of print.

Salek M, Oak N, Hines MR, Maciaszek JL, Tatevossian R, Sharma A, Nichols KE, Campbell P. Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH. Blood Adv 2022.

Hu Y, Caldwell KJ, Onciu M, Federico SM, Salek M, Lewis S, Lei S, Zhang J, Nichols KE, Takemoto CM, Triplett BM, Farrar JE, Rubnitz JE, Ribeiro RC, Wlodarski MW. CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood Adv 6(2):521-527, 2022.

Bourque MS, Salek M, Sabin ND, Canale M, Upadhyaya SA. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatr Blood Cancer 68(4):e28814, 2021.

Andrychiewicz A, Konarska K, Gorka K, Bartyzel S, Salek M, Biedron G, et al. Evaluation of factors that influence anxiety and satisfaction in patients undergoing bronchofiberoscopy with analgosedation. Clin Respir J 11(5):566-73, 2017.

Last update: August 2022

Close